2025-05-28-Jefferies-恩特罗医疗保健（ENTERO）_第四季度业绩未达预期且2026财年指引低于预期_将Entero评级下调至持有_12页_613kb

4Q Miss and Lower Than Expected FY26 Guidance, Downgrade Entero to Hold

Core Content

Entero Healthcare reported 4QFY25 results that fell short of expectations, with revenue and EBITDA below estimates. The company also provided FY26 guidance that was lower than anticipated, leading to a downgrade from Buy to Hold. The price target was revised to INR1,320, reflecting a 25x multiple on FY27 EPS.

Key Financial Performance

• 4QFY25 Revenue: INR13.4bn (+29% YoY/-1% QoQ), 6% below estimates.
• 4QFY25 EBITDA: INR0.5bn (+70% YoY/-2% QoQ), 5% below estimates.
• 4QFY25 PAT: INR0.26bn (+23% YoY/+1% QoQ), 6% below estimates.
• EBITDA Margin: Flattish at 3.7% QoQ.
• Organic Growth: 11% YoY, lower than the previous quarters' 15-17%.
• Acquisition Contribution: INR2.25bn for 4QFY25, with six new acquisitions expected to close by August 2025.

New Acquisitions

• Entero plans to acquire a controlling stake (70-80%) in six distributors.
• Combined FY25 sales of these entities: ~INR4.8bn (~9.4% of FY25 sales).
• Acquisitions are expected to enhance geographical reach and portfolio in trade generics, specialty pharma, medical consumables, and devices.
• Two acquisitions in Delhi, with combined annualized sales of INR1.78bn, are in specialty pharma and expected to have higher margins than traditional medicine distribution.

FY26 Guidance and Implications

• Revenue Growth: Guided at 30%+ vs. our expectation of 34% YoY.
• EBITDA Margin: Guided at 4% vs. our expectation of 4.5%.
• EPS Impact: Expected 15-20% EPS cuts due to lower growth and margin profile.
• Operating Cash Flow (OCF): Expected to be positive in FY26, with ~INR0.5bn generated in 2HFY25 but negative for the full year due to 1H outflows.

Company Metrics and Expansion

• Retail Customers: Increased to 95.3K from 86.3K in FY24.
• SKUs: Increased to 80.6K from 68.9K in FY24.
• Districts Covered: Reached 500 from 482 in FY24.
• Warehouses: Increased to 101 from 79 in FY24.

Investment Thesis and Downgrade Rationale

• Acquisition Pace: Slower than expected, impacting growth.
• Organic Growth: Slowed due to lower industry growth and lack of acquisitions.
• Margin Expansion: Moderated due to lower revenue growth.
• Downgrade to Hold: Based on inconsistent performance and lower growth expectations.

Revised Estimates

Valuation Scenarios

• Base Case: INR1320, -2%, with revenue growth of 25% during FY25-27E and EBITDA margin of 4.8% by FY27.
• Upside Scenario: INR1560, +16%, with revenue growth of 27% and EBITDA margin of 5% by FY27.
• Downside Scenario: INR1100, -19%, with revenue growth of 23% and EBITDA margin of 4.6% by FY27.

Key Risks and Considerations

• Downside Risks: Slower organic growth, delays in acquisition closures, high valuations for acquisitions, and inability to derive operating leverage.
• Upside Risks: Faster industry growth and rapid margin expansion.

Analyst Certification and Disclaimer

• Alok Dalal and Dhawal Khut, non-US analysts, certify the views expressed in the report.
• The report does not provide investment recommendations specific to individual investors.
• Past performance is not indicative of future results.
• The price target is based on 25x FY27 EPS, unchanged from previous estimates.